Sana Biotechnology, Inc. 8K

Sana Biotechnology, Inc. furnished a September 2026 corporate presentation describing its near‑term clinical and development plans for SC451 hypoimmune islet cell therapy and in vivo CAR T programs SG293 and SG227.

The Form 8-K includes Sana Biotechnology, Inc.’s Exhibit 99.1, a September 2026 corporate presentation outlining the company’s development strategy and timelines for its hypoimmune cell therapy SC451 for type 1 diabetes and its in vivo CAR T platforms SG293 and SG227, emphasizing goals to file an IND and start a Phase 1/2 trial for SC451 in 2026, advance in vivo CAR T programs toward first-in-human and early clinical studies, and describing supporting nonclinical, manufacturing, and regulatory activities as well as a collaboration with Mayo Clinic.

Filing Facts

CIK

1770121

Ticker

SANA

Form

8K

Source Type

fda

Accession

0001193125-26-384405

Alert Tier

5